drugset
drugset / Trial / NCT05620823

A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa

NCT05620823 ↗

Phase 3 Completed 608 enrolled Incyte Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707) in participants with moderate to severe Hidradenitis Suppurativa (HS) over a 12-week placebo controlled period, followed by a 42-week extension period.

Timeline

Start
2022-12-19
Primary completion
2025-02-03
Completion
2025-12-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Povorcitinib Small molecule — Oral

Indications

hidradenitis suppurativa